Lucid Diagnostics Inc.
Lucid Diagnostics develops and commercializes medical diagnostic products focused on detecting esophageal precancer and cancer in people at risk, including patients with gastroesophageal reflux disease. Its main products are EsoGuard, a DNA test that analyzes esophageal cells, and EsoCheck, a swallowable device used to collect those cells. LucidDx Labs operates the company’s CLIA-certified, CAP-accredited laboratory in Lake Forest, California, where EsoGuard testing is performed. Lucid makes money by providing EsoGuard testing through its own Lucid Test Centers, physician offices, mobile testing, testing events, health-system programs, telemedicine referrals and cash-pay services. It also pursues payment from commercial insurers and other payors. Lucid is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LUCD in the last 30 days.
See all $LUCD insider activity →Lucid Diagnostics reported Q3 2026 earnings, with $1.2M in revenue from EsoGuard tests. Medicare now reimburses EsoGuard nationwide, boosting commercialization. The company performed 2,871 tests in Q3 and expects growth. Lucid had a GAAP net loss of $6.7M and raised $15M in financing. A conference call was held on November 12, 2026.
Lucid Diagnostics (LUCD) announced the publication of a large-scale study on its EsoGuard® Esophageal DNA Test and EsoCheck® Device, showing rapid and well-tolerated cell collection in 11,991 patients. The study reported a 95% success rate, minimal discomfort, and high patient satisfaction. Lucid's CEO highlighted the feasibility of large-scale implementation, supported by nationwide Medicare reimbursement.
Bolt Biotherapeutics (BOLT) rose 66% after a reverse merger and $120M private placement. Lycia Therapeutics (LYCA) gained 67% in its IPO debut, raising $317.5M. Lucid Diagnostics (LUCD) climbed 28% on Medicare reimbursement for its EsoGuard test. Genmab (GMAB) advanced 10% after positive Phase 3 ovarian cancer trial results.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning LUCD (Lucid Diagnostics Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent LUCD coverage spans corporate actions, earnings and financial news.
The new Medicare coverage and increased test volume are expected to boost revenue and improve cash flow.
Positive clinical data likely to lift LUCD stock as investors price in expanded adoption.
Reimbursement approval and new capital support commercial rollout.
Cash infusion may support operations and reduce financing risk, but new shares could dilute existing holders.
The Medicare reimbursement removes a key revenue barrier and the new capital strengthens the balance sheet, likely supporting near‑term share price upside.
AlphAI scores every news story that mentions LUCD with an AI model for sentiment and relevance, and aggregates insider trades from Lucid Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lucid Diagnostics reported Q3 2026 earnings, with $1.2M in revenue from EsoGuard tests. Medicare now reimburses EsoGuard nationwide, boosting commercialization. The company performed 2,871 tests in Q3 and expects growth. Lucid had a GAAP net loss of $6.7M and raised $15M in financing. A conference call was held on November 12, 2026.
Lucid Diagnostics (LUCD) announced the publication of a large-scale study on its EsoGuard® Esophageal DNA Test and EsoCheck® Device, showing rapid and well-tolerated cell collection in 11,991 patients. The study reported a 95% success rate, minimal discomfort, and high patient satisfaction. Lucid's CEO highlighted the feasibility of large-scale implementation, supported by nationwide Medicare reimbursement.
Bolt Biotherapeutics (BOLT) rose 66% after a reverse merger and $120M private placement. Lycia Therapeutics (LYCA) gained 67% in its IPO debut, raising $317.5M. Lucid Diagnostics (LUCD) climbed 28% on Medicare reimbursement for its EsoGuard test. Genmab (GMAB) advanced 10% after positive Phase 3 ovarian cancer trial results.
Lucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. On October 21, 2026, the Company entered into subscription agreements (each, a “ Series C Subscription Agreement ”) with certain accredited investors (collectively, the “ Series C Investors ”), which agreements provided for the
Lucid Diagnostics (LUCD) began receiving Medicare payments for its EsoGuard® Esophageal DNA Test at $1,938.01 per test. The company also closed a $15M private placement with existing shareholders. Proceeds will support commercial operations and working capital. Lucid aims to accelerate commercialization and secure commercial payor coverage.
Lucid Diagnostics (LUCD) received a Nasdaq notice on October 12, 2026, for failing to maintain a minimum $1.00 bid price for 30 consecutive days. The company has until April 12, 2027, to comply, with a possible 180-day extension. The stock remains listed on Nasdaq.
Lucid Diagnostics (LUCD) shares dropped 27% to $0.55 on October 1, 2026, with no clear cause. Analysts remain optimistic, citing reimbursement advancements. The company's P/S ratio is 15.74, below its historical median. Insiders and investment gurus show mixed activity. Lucid operates in medical diagnostics, focusing on GERD-related products.
Lucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Lucid Diagnostics Advances Multiple EsoGuard ® and EsoCheck ® Payment, Billing and Coding Pathways Medicare Advisory Panel recommends maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a n
Lucid Diagnostics (LUCD) announced progress in payment, billing, and coding for its EsoGuard and EsoCheck products. CMS recommended maintaining EsoGuard's payment basis, AMA approved a new CPT code for EsoCheck, and CDC/NCHS favorably responded to a new ICD-10 code for EsoGuard results. Lucid expects to submit Medicare claims for tests performed at its Texas lab this month.
Lucid Diagnostics reported Q2 2026 revenue of $1.5M, up 17% from the prior quarter. The company performed 2,770 EsoGuard tests, within its target range. Cash reserves remained at $33.4M, with $16.8M raised from a stock offering. GAAP net loss was $14.7M, or $0.08 per share. Management highlighted progress in commercial coverage and Medicare reimbursement efforts, noting a shift to higher-probability revenue sources. The company also secured $22M in convertible debt and reported a 65% claim adjud
